DKK1,251.50
2.61% yesterday
Copenhagen, Apr 04, 05:00 pm CET
ISIN
DK0010272202
Symbol
GMAB
Sector

Genmab A/S Stock price

DKK1,251.50
-390.50 23.78% 1M
-336.00 21.17% 6M
-241.00 16.15% YTD
-832.50 39.95% 1Y
-1,298.50 50.92% 3Y
-208.50 14.28% 5Y
+733.50 141.60% 10Y
Copenhagen, Closing price Fri, Apr 04 2025
-33.50 2.61%
ISIN
DK0010272202
Symbol
GMAB
Sector

Key metrics

Market capitalization DKK79.53b
Enterprise Value DKK59.46b
P/E (TTM) P/E ratio 10.21
EV/FCF (TTM) EV/FCF 7.84
EV/Sales (TTM) EV/Sales 2.76
P/S ratio (TTM) P/S ratio 3.69
P/B ratio (TTM) P/B ratio 2.17
Revenue growth (TTM) Revenue growth 30.67%
Revenue (TTM) Revenue DKK21.53b
EBIT (operating result TTM) EBIT DKK6.93b
Free Cash Flow (TTM) Free Cash Flow DKK7.58b
Cash position DKK21.10b
EPS (TTM) EPS DKK122.59
P/E forward 11.98
P/S forward 3.17
EV/Sales forward 2.37
Show more

Is Genmab A/S a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Genmab A/S Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Genmab A/S forecast:

17x Buy
65%
8x Hold
31%
1x Sell
4%

Analyst Opinions

26 Analysts have issued a Genmab A/S forecast:

Buy
65%
Hold
31%
Sell
4%

Financial data from Genmab A/S

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
21,526 21,526
31% 31%
100%
- Direct Costs 985 985
-
5%
20,541 20,541
-
95%
- Selling and Administrative Expenses 3,865 3,865
17% 17%
18%
- Research and Development Expense 9,749 9,749
28% 28%
45%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 6,927 6,927
30% 30%
32%
Net Profit 7,844 7,844
80% 80%
36%

In millions DKK.

Don't miss a Thing! We will send you all news about Genmab A/S directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

Head office Denmark
CEO Jan Winkel
Employees 2,682
Founded 1998
Website www.genmab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today